This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Collagen-binding peptide increased trabecular thickness, collagen content, and osteoblast differentiation markers (RUNX2, osteocalcin) in a CP mouse model developed from clinical transcriptome analysis of 119 CP patients.
Why it matters
Bone loss in cerebral palsy causes fractures and pain but has no approved drug treatment. A peptide that directly stimulates bone building could fill this critical gap.
The numbers in context
119 CP patients; SPP1 downregulated; 140 mice; CBP increased trabecular thickness, collagen, bone turnover; RUNX2 and osteocalcin upregulated vs saline
How the study worked
Translational study: transcriptome analysis of 119 CP patients and 13 healthy controls, development of a hypoxic-ischemic brain injury CP mouse model (140 mice), and testing of collagen-binding peptide vs saline control.
Who was studied
119 cerebral palsy patients, 13 healthy controls (clinical); 140 mice with hypoxic-ischemic brain injury CP model (preclinical)
What this study cannot tell us
Mouse model may not fully replicate human CP bone loss. The collagen-binding peptide was tested only short-term. No comparison to existing osteoporosis drugs. Human clinical trials are needed.
Read the original research
Collagen-binding peptide reverses bone loss in a mouse model of cerebral palsy based on clinical databases.
Annals of physical and rehabilitation medicine, 64(3), 101445
Citation
Shin, Yoon-Kyum; Heo, Jeong Hyun; Lee, Jue Yeon; Park, Yoon-Jeong; Cho, Sung-Rae. (2021). Collagen-binding peptide reverses bone loss in a mouse model of cerebral palsy based on clinical databases.. Annals of physical and rehabilitation medicine, 64(3), 101445. https://doi.org/10.1016/j.rehab.2020.09.009